Dianthus Therapeutics
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $1,863 | $874 | $457 | $924 |
Gross Profit | 1,752 | 767 | 354 | 905 |
EBITDA | -22,093 | -17,844 | -12,853 | -15,743 |
EBIT | -22,204 | -17,951 | -12,956 | -15,762 |
Net Income | -17,607 | -13,748 | -10,563 | -14,763 |
Net Change In Cash | 1,863 | 874 | 457 | 924 |
Free Cash Flow | -14,545 | -14,973 | -11,864 | 1,642 |
Cash | 314,169 | 329,724 | 132,324 | 157,282 |
Basic Shares | 34,227 | 25,665 | 14,817 | 39,068 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
Revenue | $2,826 | $6,417 | $1,476 |
Gross Profit | 2,471 | 6,270 | -544 |
EBITDA | -47,819 | -29,694 | -13,060 |
EBIT | -48,174 | -29,841 | -15,080 |
Net Income | -43,555 | -28,476 | -13,109 |
Net Change In Cash | 2,826 | 6,417 | 1,476 |
Free Cash Flow | -36,971 | -29,209 | -9,937 |
Cash | 132,324 | 15,365 | 7,638 |
Basic Shares | 5,153 | 874 | 3,434 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-06-30 | -$0.51 |
2024-03-31 | -$0.54 |
2023-12-31 | -$0.71 |
2023-09-30 | -$3.78 |
